Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT06465953

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod…

This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received trea…

United States48 participantsStarted 2024-12-03

Treatment: Ivosidenib, Azacitidine

Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod…

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod…

All recent trials (1 shown)